Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 10/20 | 0.65 |
| ▸ | ORAI1 | Q96D31 | 10/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | IL2 | P60568 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16463729 | 0.96 | STIM1 (0.62) | STIM1ORAI1GAAMEN1KMT2A | |
| SCHEMBL16464082 | 0.92 | STIM1 (0.57) | STIM1ORAI1 | |
| SCHEMBL17052588 | 0.91 | STIM1 (0.55) | STIM1ORAI1IL2 | |
| SCHEMBL16463875 | 0.85 | STIM1 (0.61) | STIM1ORAI1GAAMEN1KMT2A | |
| SCHEMBL10201082 | 0.83 | STIM1 (0.56) | STIM1ORAI1GAA | |
| SCHEMBL10201056 | 0.82 | STIM1 (0.82) | STIM1ORAI1MEN1KMT2AKDR | |
| SCHEMBL10201057 | 0.82 | STIM1 (0.82) | STIM1ORAI1MEN1KMT2AKDR | |
| SCHEMBL12155590 | 0.81 | STIM1 (0.56) | STIM1ORAI1MEN1KMT2AIL2 | |
| SCHEMBL10201072 | 0.81 | STIM1 (0.60) | STIM1ORAI1 | |
| SCHEMBL15164978 | 0.81 | STIM1 (0.60) | STIM1ORAI1MEN1KMT2AIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | claimed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | claimed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | claimed |
| WO-2014059333-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-04-17 | — | — | WO | claimed |
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
| WO-2014059333-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014059333-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885GAA 994/4885 |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885GAA 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.